Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Recruiting now · Not applicable

Conditions studied: Uveal Melanoma

In brief

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

Key facts

Study ID

NCT04424719

Run by

Institut Curie

People needed

700

Starts

2020-07-08

Expected to finish

2037-07-07

Last updated by the study team

2025-09-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient aged of 18 years or more.
• Patient with uveal melanoma with high metastatic relapse risk defined as :
• T2b/c/d ou ≥ T3,
• or chromosom 3 or chromosom 8 abnormality by CGH array.
• Completion of treatment of the primary tumor ≤ 2 months.
• Patient able to comply with the schedule of visits and blood samples of the study.
• Signed informed consent form or legal representative.

You may not qualify if…

• Patient without french social insurance.
• Any social, medical or psychological condition making the research process impossible.

Where it is running

• Institut Curie — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.